日本語 
Français 
The annual event for international companies in France, “Les États de la France”, was held yesterday in Paris. The British company GSK was awarded the Choose France Ecological Transition and Decarbonisation prize for its ambitious projects (in particular, the one led in Atlantic France).
The pharmaceutical company GSK has a plant in Mayenne (Atlantic France) dedicated to the manufacturing of penicillin-based antibiotics. Founded in 1960, this world-renowned site employs more than 400 people and is constantly recruiting to increase its production capacity, which has almost doubled to 2 million boxes of medicine per week.
Close to 75% of the production is distributed to more than 110 countries, and over recent months, the British group has invested €22 million in the modernisation of the site’s infrastructure by means of digitalisation and automation of the processes.
A reward for ecological transition and decarbonisation
During the États de la France 2023, which was held on the 23rd of November in Paris, the Choose France prizes were awarded. The aim of these awards is to promote international companies investing in the French economy. Last June, the Choose France summit announced 28 international investment decisions, representing a total of €13 billion and the creation of 8000 jobs.
For its responsible commitments at the Mayenne plant, GSK was awarded the Ecological Transition and Decarbonisation prize. As a matter of fact, the Mayenne site has one of the smallest carbon footprints of all the GSK groups and has been actively participating in the zero landfill waste programme since 2012. The company has also been working to preserve biodiversity by installing beehives.
We congratulate GSK on the recognition they have received, for it is an award for a positioning that makes total sense: anchoring industrial activities in France to gain sovereignty and set an example on environmental issues.
